# Israel Cancer Research Fund

Source: https://onco.cc/institutions/icrf/  
OnCo record `icrf` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A US charity, founded in 1975, that funds cancer research by scientists in Israel; grantees' work contributed to Doxil, to Gleevec and to understanding p53.

## Summary

Israel Cancer Research Fund was founded in 1975 by Dr Daniel G. Miller and a group of American and Canadian physicians, scientists and philanthropists to help keep talented scientists in Israel by funding their work, according to its history page. It funds scientists at all career stages across 13 Israeli academic and medical institutions and describes itself as the largest nongovernmental funder of early-stage cancer research in Israel. Its history page credits ICRF-funded researchers with work on p53 as a tumour suppressor (Moshe Oren, 1987), the liposomal chemotherapy Doxil (Alberto Gabizon, 1995) and research that contributed to Gleevec (Eli Canaani, 2001), and says lifetime funding passed $100 million in 2025. The IRS Business Master File lists revenue of about $9 million for the tax year ending December 2024.

## Fields

- Kind: Institution
- Last checked: 2026-11-04
- Also known as: Israel Cancer Research Fund Inc; ICRF
- City: New York, NY, US
- Type: consortium
- Website: https://www.icrfonline.org

## Sources

- About ICRF: https://www.icrfonline.org/about-us/
- ICRF: history: https://www.icrfonline.org/history/
- IRS record (via ProPublica Nonprofit Explorer): https://projects.propublica.org/nonprofits/organizations/510181215

## Connected records

- people: [Alberto Gabizon](https://onco.cc/people/alberto-gabizon/), [Moshe Oren](https://onco.cc/people/moshe-oren/)

---
JSON: https://onco.cc/api/v1/entities/icrf.json